Catheter ablation of ventricular tachycardia: Lessons learned from past clinical trials and implications for future clinical trials.

ABSTRACT: Catheter ablation of ventricular tachycardia (VT) has evolved in recent years, especially in patients with ischemic heart disease. Data from prospective studies show that VT catheter ablation reduces the risk of recurrent VT; however, there is a paucity of data on the effect of VT catheter ablation on mortality and patient-centered outcomes such as quality of life. Performing randomized clinical trials of VT catheter ablation can be fraught with challenges, and, as a result, several prior trials of VT catheter ablation had to be stopped prematurely. The main challenges are inability to blind the patient to therapy to obtain a traditional control group, high crossover rates between the 2 arms of the study, patient refusal to participate in trials in which they have an equal chance of receiv

SUBMITTER: Pokorney SD 

PROVIDER: S-EPMC5070490 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature